Neamati's work primarily focuses on cancer and HIV. He currently has compounds at various stages of development - from theoretical to in vitro to in vivo. Some of these compounds have been shown to work in experimental mouse disease models while exhibiting no toxicity. Collaborating with colleagues at the Norris Cancer Center, Neamati aims to take these promising therapeutics into clinical trials. His research has also developed compounds for diabetes, and through collaboration, has discovered a drug for muscular dystrophy that is currently in the early stages of development.
research on diseases